Menopause: The Definitive Guide

What is menopause?

Menopause marks the end of menstrual cycles caused by the natural change in ovarian activity. In a person aged 45 or older with the appropriate history, it is generally identified after 12 months without a period when hormonal contraception does not explain the absence. The transition before it is perimenopause; the stage afterward is postmenopause. Symptoms can occur before, around and after that date. Menopause is a stage of life, not a promise that symptoms end after the twelfth month. [1], [2], [3]

The distinction helps organize care, but treatment should address what you actually need. Hot flashes, night sweats, vaginal dryness, difficult sleep or other concerns can deserve assessment. Some people have little disruption; others need substantial support. A person who feels well does not automatically need systemic HRT, and a person with persistent symptoms does not lose the right to a discussion because the final period was years ago. [1], [3], [5]

This guide concerns menopause care rather than every use of hormone replacement. Premature ovarian insufficiency, menopause before 45, surgical ovary removal and treatment-induced menopause have different contexts, including younger-age replacement and longer-term health assessment. See the separate POI, early menopause and surgical menopause guides. [1], [2]

How do you know whether menopause has occurred?

If you have had a hysterectomy, clinicians can consider the symptom pattern rather than relying on periods that are no longer observable. Tell them whether the ovaries were removed as well. A hysterectomy and an oophorectomy are different operations; the phrase “surgical menopause” should not obscure the actual procedure. Your operation also affects the discussion about which hormones may be needed. [1], [6]

In otherwise healthy people aged 45 or older with typical symptoms, NICE discourages laboratory and imaging tests such as estradiol, anti-Müllerian hormone or ovarian scans solely to identify menopause. FSH has particular younger-age uses and should not be used to identify menopause during combined estrogen/progestogen contraception or high-dose progestogen use. An age-specific diagnosis and an investigation for another illness are different reasons to test. [1]

The 12-month definition should not be used to dismiss new bleeding as simply restarting the clock. After menopause, unexplained bleeding needs assessment, even when it is light or happens once. HRT can create a separate bleeding context that requires review of the actual regimen. Tell the clinician whether you are taking systemic hormones and whether a withdrawal bleed is expected. [1], [7], [10]

Which treatment options fit your main concern?

HRT can be effective for vasomotor symptoms, and selected products can prevent bone loss. The choice is individual: what symptoms need treatment, your age and time since menopause, medical history, route, formulation, need for uterine protection and preferences. A “best HRT” list cannot answer those questions without the clinical context. If you do not want systemic treatment, say so; alternatives and local treatment are separate conversations. [1], [4], [5]

Discuss practical use as part of the decision. A patch has its own replacement interval and adhesion instructions. A gel has product-specific amounts, drying and contact precautions. Oral treatment has different handling and risk considerations. Preference can matter because a plan that is difficult to use consistently may be less useful in daily life. Product instructions belong to the named prescription, not a conversion chart shared online. [4], [5]

The same principle applies to nonhormonal medicines. They differ in indication, tolerability, interactions and monitoring. A label such as “nonhormonal” or “natural” is not evidence of safety or equivalence. Ask what symptom the option is meant to treat, how benefit will be assessed and which safety checks apply. [1], [4]

Why does uterus status change HRT?

With a uterus present, systemic estrogen usually needs an adequate progestogen component to protect the endometrium, the lining inside the uterus. Without sufficient opposition, estrogen can encourage excessive lining growth. Progesterone is one progestogen; the selected product, route, amount and exposure days determine how a prescription supplies protection. Symptom relief or the absence of bleeding does not certify that protection is adequate. [1], [6]

After a total hysterectomy, estrogen-only HRT is usually offered. Partial hysterectomy, endometriosis or other particular histories can change the discussion. Removing the ovaries does not remove the uterus; if the uterus remains, the protection question remains. Confirm the operation and the complete regimen rather than guessing from whether you still have periods. [1], [6]

Continuous combined HRT supplies estrogen and progestogen continuously and is generally used after menopause. Sequential treatment supplies progestogen on particular days and often produces a planned withdrawal bleed. These terms describe schedules, not two universally interchangeable doses. The progesterone guide separates labeled and guideline examples by product and country. [4], [6]

Do not replace that protection with a compounded progesterone skin cream or remove the progestogen because it causes unwanted effects. BMS describes variable transdermal absorption and insufficient protection evidence for such preparations. Oral-to-vaginal changes also have evidence and authorization limits that belong in a prescribing discussion. If a component is difficult to tolerate, ask to revise the whole plan. [6]

When is local vaginal treatment enough?

Vaginal dryness, irritation, discomfort with sex and related urinary symptoms can persist independently of hot flashes. Low-dose vaginal estrogen is offered for menopausal genitourinary symptoms, including when systemic HRT is already being used. Moisturizers and lubricants can also help in their respective roles. Adding local treatment does not mean that the systemic prescription has failed at every purpose. [1], [4], [5]

Low-dose local treatment usually has much less systemic exposure than systemic HRT. That is a product and treatment-purpose distinction, not a statement that every vaginal medicine acts only locally. Some vaginal rings deliver systemic estrogen. Ask whether the named product is local or systemic and whether it changes the uterine-protection plan. [1], [6], [13]

A history of breast cancer calls for a more individualized conversation, especially during aromatase-inhibitor treatment. NICE gives separate recommendations for that context. Persistent pain, discharge, urinary symptoms or bleeding may also have another cause; they should not automatically be managed by increasing estrogen. The GSM guide covers that assessment and treatment discussion. [1]

How should you weigh benefits and risks?

The decision starts with the intended benefit and your baseline risk. Discuss cancer history, previous clots, stroke or heart disease, unexplained bleeding, blood pressure, medicines and other significant conditions. A history may change the options or make specialist input appropriate. A transdermal route can be considered where venous-clot risk is increased under NICE guidance, but it does not override every product contraindication or make treatment universally risk-free. [1], [4], [5]

The 2022 North American Menopause Society statement describes a more favorable benefit-risk balance for symptomatic people younger than 60 or within 10 years of menopause onset who have no contraindications. Starting later requires greater attention to age-related absolute risks. This is a framework for individual decisions, not a birthday deadline, a promise of zero harm or a requirement that everyone use HRT. The abstract was reviewed for this guide; it does not give a personal risk estimate. [5]

NICE distinguishes combined HRT from estrogen-only treatment in its breast-risk discussion. Combined treatment is associated with increased breast-cancer risk; duration and baseline risk affect the practical meaning. A relative risk without the outcome, comparator, denominator and time period can be misleading. Ask for those details and whether the estimate applies to your actual regimen. This guide does not transfer a WHI result from oral conjugated estrogens and medroxyprogesterone to every modern estradiol preparation. [1], [5]

Balance risks with meaningful symptom relief and the alternatives. Treatment is reassessed over time because health, symptoms and preferences can change. HRT is not a prescription to reverse aging, guarantee weight loss or prevent dementia or cardiovascular disease. A decision to start, continue, change or stop should address the indication rather than a broad claim that hormones are essential for every cell. [1], [5]

What should happen to bone and general health care?

Menopause is a useful time to review bone health and ordinary cardiovascular prevention. Consider physical activity, strength and balance, nutrition, smoking, alcohol, blood pressure and other relevant health factors with your clinician. HRT can reduce fracture risk while taken, but that does not establish that it is the best or only treatment for every person with osteoporosis. Fracture history and individual risk affect the assessment. [1], [4], [5]

Symptoms and longer-term health are related but different questions. Feeling better does not replace nationally recommended screening, and no hormone test certifies protection from a future fracture or cardiovascular event. If you stop a treatment used partly for bone protection, discuss what should replace that role. The heart and bone health guide expands this discussion. [1], [5]

People with POI or early menopause can need replacement care for reasons beyond hot-flash relief. Do not import a usual-menopause-age decision rule into that younger group. Equally, do not import a young person's replacement amount into a later-life symptom-treatment plan. The indication and population remain attached to the evidence. [1], [5]

How long can symptoms continue after the final period?

The final period and the end of symptoms are not the same event. NHS information describes symptoms during perimenopause and afterward, with substantial variation. Some symptoms improve, some persist and some need different care. Neither a calendar milestone nor another person's recovery supplies your expected timeline. [2], [3]

An original SWAN observational duration analysis helps put persistence in context. Among 881 participants with frequent vasomotor symptoms and an observable final menstrual period, median persistence after that period was 4.5 years. Frequent meant hot flashes or night sweats on at least six days during the previous two weeks. The median is the middle value in that selected symptomatic group, not the experience of all people after menopause. [9]

The study observed symptom duration; it did not assign HRT to prove a treatment effect or establish how long any person should stay on a medicine. Its broader analysis of 1,449 participants found a median total frequent-symptom duration of 7.4 years across the transition. The post-period and total durations are different outcomes and samples; they should not be combined into a personal countdown. [9]

Which bleeding should you report?

After menopause, unexplained vaginal bleeding should be assessed, even if it happens once, is light or looks like brown or pink discharge. Many causes are not cancer, but a reassuring resemblance to an old period cannot rule out a problem. Tell the clinician when bleeding began, how much there is, associated pain and all hormone or other medicines used. [10]

For systemic HRT, the expected pattern depends on the regimen. NICE's amended 2026 advice says bleeding is common in the first six months of treatment or within three months of changing dose or preparation, with prompt medical help beyond those windows. BMS provides earlier investigation exceptions for heavy or prolonged bleeding and certain risk factors. Do not wait for a timeframe to end if the bleeding is concerning. [1], [7]

Unexpected bleeding deserves assessment of the whole situation, including adherence and uterine protection, rather than automatic dose escalation. Very heavy bleeding with faintness, severe pain or acute illness requires urgent care. An examination, ultrasound or biopsy may be recommended for a particular clinical question; this guide does not provide a self-triage thickness cutoff. [7], [10]

What does ongoing review involve?

NICE recommends reviewing treatment for menopause symptoms at three months, then annually, or earlier for ineffectiveness or unwanted effects. Review the indication, benefits, tolerability, bleeding, correct use and relevant health changes. If symptoms remain troublesome, the clinician may revisit the diagnosis, treatment or need for specialist advice. A follow-up should make the next step clearer rather than merely supplying another prescription. [1]

There is no universal mandatory end date for symptom treatment. NAMS supports longer use for documented indications with shared decisions and periodic reassessment. Some product labels describe tapering or stopping attempts; follow the named medicine and clinical plan rather than treating a general overview as its replacement. The stopping guide addresses that later conversation. [1], [5]

Pregnancy prevention can still need discussion when menopausal status is uncertain or when hormones obscure bleeding. The FSRH guideline bases stopping contraception on age, method and circumstances. An HRT prescription or absent withdrawal bleed does not replace those rules. [8]

What do public discussions add?

Two public discussions illustrate questions that remain after the transition: how to interpret bleeding after a long bleed-free interval, and how long HRT might be needed. The first contains personal reassurance as well as concern about assessment; the second mixes benefit, unwanted effects and uncertainty about duration. These are selected experiences, not diagnostic evidence, a current survey or a prescription rule. [11], [12]

The useful distinction is between a question and a conclusion. Another person's “period came back” account does not make postmenopausal bleeding safe to ignore. A claim of lifelong treatment does not determine your duration. Bring the concern to a clinician and ask which history, product instructions and evidence apply. The guide uses the threads for themes only, without usernames, votes, copied personal narratives or source doses. [1], [5], [10], [11], [12]

What should you keep in a practical record?

Record the exact product, route and schedule, treatment start and changes, missed applications, symptom goals, bleeding and unwanted effects. Keep a short summary of what has improved and what has not. Describe whether sleep improved because night sweats stopped or whether another sleep problem persists. These notes organize the review; they do not prove that HRT caused every change or set a hormone target. [1]

Include relevant operations, contraception or an IUD's name and insertion date. Bring current medicines and supplements to appointments, and ask whom to contact for problems before the next review. Doserly tracks the schedule you and your clinician choose. It does not recommend doses. [1], [6], [8]

Common questions about menopause

Do symptoms stop after 12 months without a period?

Not necessarily. The 12-month milestone identifies a stage in the right context; symptoms can persist or change afterward. Care should respond to their actual effect rather than assuming the calendar has solved them. Tell the clinician which symptoms still disrupt sleep, work or comfort and which have improved. That distinction helps clarify the treatment goal and whether a different problem needs assessment. Reaching menopause is useful context, but it is not a deadline for recovery. See what menopause means. [2], [3], [9]

Does everyone need HRT after menopause?

No. The decision depends on symptoms, indication, history and preferences. Discuss benefits, risks and alternatives; having reached menopause alone is not a requirement to start systemic treatment. Younger ovarian insufficiency has a separate replacement context. If symptoms are not troublesome, there is still value in ordinary preventive care. If they are disruptive, the discussion should identify the problem you want treated and a suitable option, rather than treating menopause status as an automatic prescription. See choosing treatment. [1], [5]

Is it too late to discuss symptoms if I am over 60?

You can still seek care after 60. Starting systemic HRT later has a different benefit–risk discussion and may require more assessment; local treatment and nonhormonal options are separate choices. An age framework is not permission to dismiss distress or an instruction to start without review. Bring your menopause timing, previous treatment and current health concerns to the appointment. These help the clinician discuss the actual indication and alternatives, instead of making the decision from age alone. See benefits and risks. [1], [5]

Do I need progesterone after a hysterectomy?

After total hysterectomy, estrogen-only HRT is usually offered, but particular histories can change the plan. Confirm the operation and circumstances. Removing ovaries alone does not remove the uterus or the protection question. If the proposed regimen includes a progestogen despite hysterectomy, ask what part of your history explains that choice. Knowing the organs removed and any relevant residual disease is more useful than the shorthand “everything was removed.” See uterine protection and operation details. [1], [6]

Can vaginal treatment be used with a patch?

Yes, low-dose local vaginal estrogen may be offered when genitourinary symptoms persist despite systemic HRT. The clinician should confirm the symptom cause and named product. It does not replace protection needed for a systemic regimen with a uterus. Explain whether dryness, pain or urinary concerns remain even when hot flashes improve. Different symptoms can need different care, and adding local treatment is a product-specific discussion rather than a reason to increase the patch yourself. See local treatment. [1], [6]

Is light spotting after menopause harmless?

It still needs assessment. The amount alone cannot rule out an important cause, and systemic HRT has a regimen-specific bleeding context. Report the timing, any expected scheduled bleed and changes to your medicines. Do not assume it is another natural period or adjust hormones through a forum. The assessment may identify several possible explanations; asking for review does not mean a serious diagnosis is already established. See which bleeding needs attention. [7], [10]

Does improved sleep prove that my hormone plan is safe?

No. Benefit is one part of review. Bleeding, adverse effects, contraindications, screening and required uterine protection still matter. Feeling better is useful information, not a safety certificate. Describe both a meaningful improvement and any remaining difficulty so the clinician can assess the complete plan. Keep the actual products and schedules available, including a separate protective medicine where prescribed. A good response should support a considered follow-up rather than replace it. See treatment review. [1], [6]

Can I decide now how many years I will take HRT?

You can discuss an initial plan and review points, but the decision should be revisited as symptoms, benefits, risks and preferences change. There is no single fixed duration that fits every indication or person. Ask what would support continuation, what would prompt an earlier review and how a future stopping decision would be approached. Those questions make the plan more useful than a promise to continue or stop on one predetermined date. See follow-up and duration. [1], [5]

Glossary

Terms used in menopause assessment and care.

Perimenopause

The transition toward menopause, with changing ovarian hormone patterns and possible symptoms.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excessive growth of the uterine lining; distinct from a cancer diagnosis.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Local vaginal estrogen

A low-dose product intended mainly for genitourinary symptoms.

Vasomotor symptoms

Hot flashes and night sweats.

Genitourinary syndrome of menopause

A group of menopause-associated vaginal, sexual and urinary symptoms.

FSH

Follicle-stimulating hormone; interpretation depends on age, stage and medicines.

Premature ovarian insufficiency

Loss or disturbance of ovarian activity before age 40, requiring its own assessment.

Hysterectomy

Surgical removal of the uterus; the extent of surgery matters.

Oophorectomy

Surgical removal of one or both ovaries.

Sequential combined HRT

Estrogen through the cycle with progestogen on specified days.

Continuous combined HRT

Estrogen and progestogen supplied continuously.

Withdrawal bleeding

Bleeding that can follow completion of a scheduled progestogen course.

Unscheduled bleeding

Bleeding outside the expected pattern of the agreed treatment.

Contraception

A method intended to prevent pregnancy; menopausal HRT is not one.

IUD

Intrauterine device; type and indication determine its role.

CBT

Cognitive behavioural therapy; menopause-specific approaches address particular symptoms.

Bioidentical

Chemically identical to a hormone made by the body; not a guarantee of safety.

Compounded preparation

A specially prepared medicine, not automatically equivalent to an approved product.

Anemia

A low hemoglobin or red-cell-related problem; heavy bleeding can prompt investigation.

Median

The middle value of a set of observations, not a personal prediction.

Observational study

A study observing people without randomly assigning the treatment being examined.

How was this guide researched?

Source selection and limits

We checked original NICE recommendations, current NHS pages, May 2026 BMS uterine-protection and bleeding guidance, FSRH contraception guidance and the NAMS 2022 PubMed abstract. The original SWAN study supplies two separate symptom-duration outcomes with their own samples; it is not an HRT trial. The older visible review date on the NHS postmenopausal-bleeding page is recorded; current systemic-HRT windows use NICE 2026 and BMS 2026. [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [13]

Public discussions supply questions about bleeding and duration, not clinical authority. One thread was directly retrieved; the other was checked through indexed public search text after direct opening failed. Access limits are retained. [11], [12]

This is an AI-assisted Doserly editorial guide, checked October 2, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical records organize a consultation; they are not a diagnostic or treatment-effect measurement. Material new labels, guidance or safety information trigger source review.

Sources